Preferred Label : quinolines;

Wikipedia automatic translation : Quinoline;

MeSH annotation : do not confuse with QUINOLIZINES nor with QUINOLONES nor its X ref QUINOLINONES;

Wikipedia link : https://en.wikipedia.org/wiki/Quinoline;

Is substance : O;

Details


Main resources

You can consult :


https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/default-d6182e9e12-99.html
2021
false
false
false
Canada
French
drug evaluation
quebec
cystic fibrosis
adolescent
adult
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
CFTR delta F508
drug combinations
trikafta
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor, ivacaftor, tezacaftor drug combination
benzodioxoles
aminophenols
indoles
pyrazoles
pyridines
quinolines
benzodioxoles
aminophenols
drug combinations
indoles
pyrazoles
pyridines
quinolines

---
https://www.has-sante.fr/jcms/p_3191460/fr/nerlynx
2020
false
false
false
France
neratinib
administration, oral
insurance, health, reimbursement
adult
breast neoplasms
Adjuvant Chemotherapy
Hormone Receptor-Positive Breast Carcinoma
receptor, erbB-2
Trastuzumab
treatment outcome
Product containing precisely neratinib (as neratinib maleate) 40 milligram/1 each conventional release oral tablet (clinical drug)
evaluation of the transparency committee
neratinib
quinolines

---
https://www.has-sante.fr/jcms/p_3202354/fr/sirturo
2020
false
false
false
France
bedaquiline
insurance, health, reimbursement
treatment outcome
tuberculosis, multidrug-resistant
tuberculosis, pulmonary
adolescent
bedaquiline
administration, oral
antitubercular agents
evaluation of the transparency committee
diarylquinolines
quinolines

---
https://www.has-sante.fr/jcms/p_3220388/fr/kaftrio-/-kalydeco
2020
false
false
false
France
drug combinations
treatment outcome
insurance, health, reimbursement
ivacaftor
Chloride Channel Agonists
tezacaftor
ivacaftor
ivacaftor, tezacaftor and elexacaftor
cystic fibrosis
adolescent
adult
CFTR delta F508
cystic fibrosis transmembrane conductance regulator delta F508
administration, oral
elexacaftor
elexacaftor, ivacaftor, tezacaftor drug combination
evaluation of the transparency committee
aminophenols
quinolones
indoles
benzodioxoles
cystic fibrosis transmembrane conductance regulator
pyrrolidines
pyridines
pyrazoles
drug combinations
quinolines

---
https://ansm.sante.fr/informations-de-securite/montelukast-singulair-et-generiques-risque-de-survenue-deffets-indesirables-neuropsychiatriques-renforcement-des-mises-en-garde
https://ansm.sante.fr/actualites/montelukast-singulair-et-generiques-indique-dans-le-traitement-de-lasthme-lansm-rappelle-les-risques-de-survenue-deffets-indesirables-neuropsychiatriques
2020
false
false
false
France
French
mental disorders
nervous system diseases
montelukast
pharmacovigilance note
montelukast
drug monitoring
anti-asthmatic agents
acetates
quinolines

---
https://www.ema.europa.eu/en/medicines/human/EPAR/kaftrio
2020
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Product containing only elexacaftor and ivacaftor and tezacaftor in oral dose form (medicinal product form)
drug approval
europe
drug combinations
administration, oral
orphan drug production
pyrazoles
pyrazoles
pyridines
pyridines
pyrrolidines
pyrrolidines
ivacaftor
ivacaftor
tezacaftor
tezacaftor
adolescent
adult
cystic fibrosis
drug therapy, combination
cystic fibrosis transmembrane conductance regulator
ivacaftor, tezacaftor and elexacaftor
product surveillance, postmarketing
drug interactions
drug evaluation, preclinical
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor
elexacaftor
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
aminophenols
quinolones
aminophenols
quinolones
indoles
benzodioxoles
indoles
benzodioxoles
quinolines
quinolines

---
https://www.has-sante.fr/portail/jcms/c_2884088/fr/fotivda-tivozanib-inhibiteur-de-proteine-kinase
2019
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
tivozanib
tivozanib
receptors, vascular endothelial growth factor
antineoplastic agents
antineoplastic agents
carcinoma, renal cell
neoplasm metastasis
adult
treatment outcome
insurance, health, reimbursement
tivozanib
Tyrosine Kinase Inhibitors
phenylurea compounds
quinolines
phenylurea compounds
quinolines

---
https://www.has-sante.fr/portail/jcms/c_2904835/fr/izilox
2019
false
false
false
France
evaluation of the transparency committee
aza compounds
quinolines
fluoroquinolones
Moxifloxacin

---
https://www.has-sante.fr/jcms/p_3098041/fr/bosulif
2019
false
false
false
France
bosutinib
bosutinib
treatment outcome
adult
antineoplastic agents
protein kinase inhibitors
leukemia, myelogenous, chronic, bcr-abl positive
evaluation of the transparency committee
aniline compounds
nitriles
quinolines

---
https://www.has-sante.fr/jcms/p_3113418/fr/lenvima
2019
false
false
false
France
lenvatinib
treatment outcome
antineoplastic agents
protein kinase inhibitors
lenvatinib
adult
carcinoma, hepatocellular
administration, oral
evaluation of the transparency committee
Lenvima
phenylurea compounds
quinolines

---
https://www.has-sante.fr/jcms/p_3097600/fr/bosulif
2019
false
false
false
France
bosutinib
administration, oral
treatment outcome
leukemia, myeloid, chronic-phase
Philadelphia chromosome positive chronic myelogenous leukemia (disorder)
antineoplastic agents
protein kinase inhibitors
bosutinib
adult
evaluation of the transparency committee
aniline compounds
nitriles
quinolines

---
https://www.ema.europa.eu/medicines/human/EPAR/Nerlynx
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
product surveillance, postmarketing
neratinib
breast neoplasms
recurrence
HER2 positive breast cancer
Hormone receptor positive malignant neoplasm of breast (disorder)
administration, oral
breast neoplasms
protein-tyrosine kinases
receptor, erbB-2
adult
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Product containing precisely neratinib (as neratinib maleate) 40 milligram/1 each conventional release oral tablet (clinical drug)
Tyrosine Kinase Inhibitors
neratinib
neratinib
quinolines
quinolines

---
https://www.has-sante.fr/portail/jcms/c_2834705/fr/kisplyx-lenvatinib-inhibiteur-de-tyrosine-kinase
https://www.has-sante.fr/portail/jcms/c_2834705/fr/kisplyx
2018
false
false
false
France
French
lenvatinib
treatment outcome
antineoplastic combined chemotherapy protocols
carcinoma, renal cell
adult
protein kinase inhibitors
protein kinase inhibitors
antineoplastic agents
antineoplastic agents
lenvatinib
administration, oral
protein-tyrosine kinases
receptor Protein-Tyrosine kinases
evaluation of the transparency committee
guidelines for drug use
insurance, health, reimbursement
disease-free survival
Everolimus
Tyrosine Kinase Inhibitors
lenvatinib
phenylurea compounds
quinolines
phenylurea compounds
quinolines

---
https://www.has-sante.fr/portail/jcms/c_2856009/fr/izilox
2018
false
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
insurance, health, reimbursement
aza compounds
quinolines
fluoroquinolones
Moxifloxacin

---
https://www.has-sante.fr/portail/jcms/c_2884088/fr/fotivda
2018
false
false
false
France
tivozanib
tivozanib
tivozanib
administration, oral
treatment outcome
adult
carcinoma, renal cell
receptors, vascular endothelial growth factor
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
phenylurea compounds
quinolines
phenylurea compounds
quinolines

---
https://www.ema.europa.eu/medicines/human/EPAR/Kisplyx
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
lenvatinib
drug approval
europe
treatment outcome
drug interactions
antineoplastic combined chemotherapy protocols
carcinoma, renal cell
adult
protein kinase inhibitors
protein kinase inhibitors
antineoplastic agents
antineoplastic agents
lenvatinib
administration, oral
protein-tyrosine kinases
product surveillance, postmarketing
pregnancy
breast feeding
receptor Protein-Tyrosine kinases
drug evaluation, preclinical
Product containing precisely lenvatinib (as lenvatinib mesilate) 4 milligram/1 each conventional release oral capsule (clinical drug)
Product containing precisely lenvatinib (as lenvatinib mesilate) 10 milligram/1 each conventional release oral capsule (clinical drug)
Tyrosine Kinase Inhibitors
lenvatinib
phenylurea compounds
quinolines
phenylurea compounds
quinolines
phenylurea compounds
quinolines

---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-BCR-ABL-Imatinib-Dasatinib-Nilotinib-Bosutinib-Ponatinib-Medicament-ciblant-JAK-Ruxolitinib-Anticancereux-par-voie-orale-informer-prevenir-et-gerer-leurs-effets-indesirables
2016
false
false
false
France
French
practice guideline
antineoplastic agents
administration, oral
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
information dissemination
patient education as topic
drug interactions
Dasatinib
Imatinib Mesylate
fusion proteins, bcr-abl
protein kinase inhibitors
dasatinib
imatinib
nilotinib
nilotinib
bosutinib
ponatinib
ruxolitinib
janus kinases
ponatinib
ruxolitinib
bosutinib
continuity of patient care
pregnancy
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
aniline compounds
nitriles
quinolines
imidazoles
pyridazines
pyrimidines
pyrazoles

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00209
2016
false
false
false
Canada
French
English
summary of product characteristics
administration, oral
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
risk assessment
adult
thyroid neoplasms
Differentiated Thyroid Gland Carcinoma
Refractory Carcinoma
treatment outcome
Cancer Progression
drug approval
drug evaluation, preclinical
protein-tyrosine kinases
lenvatinib
canada
Lenvatinib Mesylate
Lenvatinib Mesylate
neoplasm recurrence, local
neoplasm metastasis
Tyrosine Kinase Inhibitors
lenvatinib
lenvatinib
phenylurea compounds
quinolines
phenylurea compounds
quinolines

---
BCR-ABL Tyrosine Kinase Inhibitors [GLEEVEC (imatinib mesylate), TASIGNA (nilotinib), BOSULIF (bosutinib), SPRYCEL (dasatinib), ICLUSIG (ponatinib hydrochloride)] - Risk of Hepatitis B Reactivation
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58222a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
fusion proteins, bcr-abl
protein kinase inhibitors
Imatinib Mesylate
risk
hepatitis b virus
imatinib
nilotinib
nilotinib
bosutinib
bosutinib
Dasatinib
dasatinib
ponatinib hydrochloride
ponatinib
Tyrosine Kinase Inhibitor
Hepatitis B reactivation
guidelines for drug use
continuity of patient care
mass screening
hepatitis B
hepatitis B
Tyrosine Kinase Inhibitors
nilotinib
ponatinib
pyrimidines
imidazoles
pyridazines
aniline compounds
nitriles
quinolines

---
http://www.e-cancer.fr/content/download/126025/1524695/file/Médicaments%20ciblant%20BCR-ABL.pdf
2015
false
false
false
France
French
practice guideline
guidelines for drug use
administration, oral
antineoplastic agents
Drug-Related side effects and adverse reactions
imatinib
dasatinib
nilotinib
nilotinib
bosutinib
bosutinib
ponatinib
ponatinib
protein kinase inhibitors
ruxolitinib
ruxolitinib
janus kinases
information dissemination
continuity of patient care
hospital-physician relations
hospital-patient relations
physician-patient relations
drug interactions
pregnancy
protein-tyrosine kinases
Tyrosine Kinase Inhibitor
Dasatinib
Imatinib Mesylate
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
pyrazoles
aniline compounds
nitriles
quinolines
imidazoles
pyridazines

---
Progrès thérapeutique mineur dans la prise en charge du cancer différencié de la thyroïde au stade localement avancé ou métastatique, réfractaire à l’iode radioactif
http://www.has-sante.fr/portail/jcms/c_2581320/fr/lenvima
http://www.has-sante.fr/portail/jcms/c_2581320/fr/lenvima-lenvatinib-inhibiteur-de-proteine-kinase
2015
false
false
false
France
French
administration, oral
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
risk assessment
adult
thyroid neoplasms
Differentiated Thyroid Gland Carcinoma
Refractory Carcinoma
treatment outcome
survival analysis
neoplasm metastasis
Locally Advanced Malignant Neoplasm
evaluation of the transparency committee
Cancer Progression
lenvatinib
guidelines for drug use
lenvatinib
lenvatinib
phenylurea compounds
quinolines
phenylurea compounds
quinolines

---
http://www.infectiologie.com/UserFiles/File/medias/Recos/2015-MAP-fluoroquinolones-SPILF.pdf
http://www.infectiologie.com/UserFiles/File/medias/diaporamas/recos/SPILF-groupe_reco-SPILF-FQ-2015.pptx
2015
true
false
false
France
French
guidelines for drug use
osteoarticular infections
ciprofloxacin
levofloxacin
norfloxacin
anti-bacterial agents
pefloxacin
ofloxacin
diabetic foot
Diabetic foot infection
pyelonephritis
urinary tract infections
Q fever
legionellosis
anthrax
anthrax
plague
plague
tularemia
tularemia
gonorrhea
community-acquired infections
pneumonia, bacterial
Nosocomial pneumonia
Community acquired pneumonia
cross infection
maxillary sinusitis
meningitis, bacterial
antibiotic prophylaxis
fluoroquinolones
fluoroquinolones
drug resistance, bacterial
Intestinal Flora
diarrhea
typhoid fever
Ascites infection
intraabdominal infections
mycobacterium infections
reproductive tract infections
child
adult
aged
antibiotic therapy
aza compounds
quinolines
Moxifloxacin

---
https://www.ema.europa.eu/medicines/human/EPAR/LENVIMA
2015
false
false
false
United Kingdom
French
English
package leaflet
summary of product characteristics
administration, oral
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
drug evaluation
risk assessment
adult
thyroid neoplasms
Differentiated Thyroid Gland Carcinoma
Refractory Carcinoma
treatment outcome
Cancer Progression
syndication feed
orphan drug production
drug approval
europe
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
continuity of patient care
product surveillance, postmarketing
protein-tyrosine kinases
lenvatinib
Tyrosine Kinase Inhibitors
lenvatinib
lenvatinib
phenylurea compounds
quinolines
phenylurea compounds
quinolines

---
http://www.cochrane.org/fr/CD010927/la-dihydroartemisinine-piperaquine-pour-le-traitement-du-paludisme-non-complique
false
false
false
France
United Kingdom
meta-analysis
french abstract
adult
child
antimalarials
treatment outcome
artemisinins
quinolines
drug therapy, combination
artenimol
malaria
piperaquine

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=60462965
2014
false
false
false
France
French
summary of product characteristics
package leaflet
pill, nos
compression, nos
bosutinib
bosutinib
seborrhea sicca
tablets
dandruff
bosutinib
dandruff
aniline compounds
nitriles
quinolines

---
http://www.has-sante.fr/portail/jcms/c_1730843/fr/bosulif-bosutinib-inhibiteur-de-tyrosine-kinase
2014
false
false
false
France
French
English
evaluation of the transparency committee
guidelines for drug use
administration, oral
bosutinib
bosutinib
bosutinib
adult
leukemia, myeloid, chronic-phase
leukemia, myeloid, accelerated phase
blast crisis
protein kinase inhibitors
protein kinase inhibitors
insurance, health, reimbursement
treatment outcome
survival analysis
aniline compounds
nitriles
quinolines
aniline compounds
nitriles
quinolines

---
http://www.has-sante.fr/portail/jcms/c_1792845/fr/moxifloxacine-krka
2014
false
false
false
France
French
evaluation of the transparency committee
aza compounds
quinolines
Moxifloxacin

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=63150294
2014
false
false
false
France
French
summary of product characteristics
package leaflet
bosutinib
bosutinib
tablets
pill, nos
compression, nos
bosutinib
dandruff
seborrhea sicca
dandruff
aniline compounds
nitriles
quinolines

---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=8300&nom=Quinoléine
Canada
toxicological data sheet
quinoline
quinolines
quinoline

---
http://www.lecrat.eu/?s=Montelukast
2011
France
French
pregnancy
anti-asthmatic agents
leukotriene antagonists
breast feeding
acetates
quinolines
montelukast
montelukast
acetates
quinolines
drug information

---
http://www.lecrat.eu/?s=Moxifloxacine
2009
France
French
pregnancy
aza compounds
quinolines
anti-infective agents
child
moxifloxacin
aza compounds
quinolines
drug information
Moxifloxacin

---
https://www.minerva-ebp.be/fr/article/802
2005
false
false
minerva-ebm.be
Belgium
French
Fluticasone-Salmeterol Drug Combination
asthma
anti-asthmatic agents
leukotriene antagonists
quinolines
acetates
adult
bronchodilator agents
adrenergic beta-agonists
treatment outcome
asthma
montelukast
acetates
critical appraisal or critical reading
comparative study

---
http://www.hc-sc.gc.ca/ewh-semt/pubs/contaminants/quinoline-quinoleine/index_f.html
2005
Canada
technical report
knowledge
report
quinolines
quinoline
quinoline

---
Nous contacter.
07/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.